Biotech Insider researches the stocks of small biotech companies. The biotech sector is an area where small investors have a significant advantage over large institutional investors and mutual funds, which typically consider the stocks too small to research, monitor or invest in.
What we look for: Biotech Insider looks for small & mid cap companies that are in late phase two and phase three studies. We tend to focus on companies near the end of a clinical trial cycle in an effort to mitigate risk. From time to time we will, however, focus on companies that do not meet this profile if they have great science of a broad-based approach. While these companies may be further from commercialization, they can still represent savvy investments for the patient investor.
As a member of Biotech Insider you’ll receive:
- 1 new research report each month… One new research report each month for a total of twelve for the year. These in-depth reports average 30 pages on average and clearly explain what to buy, at what price to buy it and exactly when to sell it.
- Regular updates…Whenever there is any material news on one of our portfolio companies you’ll get an email from Dylan by the end of the day, at the latest
- 24/7 access to members-only website…Where all past issues, our track record and all alerts can be found in an instant.
Behind the Markets: Independent research for independent investors.
Entrepreneur & investor Dylan Jovine is the founder & CEO of Behind the Markets, a company whose mission is to bring individual investors the same quality investment research institutional investors have.
Prior to that, in 2004, he Tycoon Publishing to offer the public independent, conflict-free investment research & education.
At its peak, the company catered to over 500,000 individual investors from over 28 countries.
In 2011, he sold Tycoon to the largest independent financial newsletter publisher in the world, Agora, Inc.
Lexington Capital Partners
In 1996, he founded brokerage and investment bank Lexington Capital Partners (LCP) on 100 Wall Street in New York City.
At 24 years old he is considered one of the youngest people in history to guide a firm through the National Association of Securities Dealers (NASD) stringent year-long Pre-Membership Interview (PMI) process.
By the time he sold his stake in the company to Silver Lake Capital in 2000, the firm made markets in over one hundred securities and generated approximately twenty-five million in annual revenue.
Writing for The Tycoon Report
Dylan is perhaps best known as a regular contributor to the free investment newsletter, The Tycoon Report.
On December 19th 2006, he made the first of several public warnings about the stock market to his readers.
In early 2009 he became bullish telling his readers that this would be “the greatest opportunity since the great depression.”
(This lead to an pretty bad appearance on Fox Business where he got to explain why he was bullish but was never invited back because he was terrible in front of the news camera).
In 2007, Mr. Jovine participated in the only investing contest he ever entered, coming in second place out of one hundred of the most popular investors in an AOL-sponsored investing contest.
When Dylan isn’t working on one of his many business interests, he spends time with his family. His hobbies include a passion for ancient Roman history and a love of writing.
Start"Cut & Paste" - The Small Company Revolutionizing Medicine
Start"Medical Money" - How to Create a Small Cap Biotech Portfolio
Start"Biotech Income" - How to Generate Extra Income from Your Biotech Portfolio Each Month
Start"Pot Stocks" - What the History of Cigarettes Tells us About Cannabis
Start"Tidal Wave Profits" - How the Medical Revolution will Change Your Relationship with Your Doctor
StartSpecial Report: 3 Key Ingredients to A Great Biotech Stock
StartBehind Trumps Trade War with China